PARATHYROID GLANDS: ANATOMO-PHYSIOLOGICAL ASPECTS AND HORMONES ACTION
Keywords:
Parathyroid glands, parathyroid hormone, calcium, phosphorus, vitamin D, vitamin D receptor, FGF23, FGFRs, Klotho proteinAbstract
In review paper, the authors presented data about anatomy and physiology of parathyroid glands, molecular mechanism of parathyroid hormone action, interaction with vitamin D, its derivatives and receptors, also explained in details the role of calcitonine, FGF23, FGFRs, calcium sensing receptor CaSR and Klotho protein. Hormonal action of PTH were described in details with illustration, especially regulation of calcium and phosphorus level in the blood plasma and in bones mineralisation. Information about disturbance of mineral metabolism and involving of parathyroid glands with development of primary, secondary and tertiary pathology described. This review presented interest for family doctors, specialist physicians such as endocrinologist, nephrologist, hemodialysis doctors, surgeons, also for students and residents.
References
Bilezikian JP, Khan A, Potts JT Jr, et al.: Hypoparathyroidism in the adult: Epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res. 2011; 26(10): 2317–37
Blaine J, Chonchol M, Levi M (2015). "Renal control of calcium, phosphate, and magnesium homeostasis". Clinical Journal of the American Society of Nephrology. 10 (7): 1257–72.
Canadillas S, Canalejo A, Santamaria R, Rodriguez ME, Estepa JC, Martin-Malo A, Bravo J, Ramos B, Aguilera-Tejero E, Rodriguez M, Almaden Y: Calcium-sensing receptor expression and parathyroid hormone secretion in hyperplastic parathyroid glands from humans. J Am Soc Nephrol 16: 2190–2197, 2005
Centeno PP, Herberger A, Mun HC, Tu C, Nemeth EF, Chang W, Conigrave AD, Ward DT: Phosphate acts directly on the calciumsensing receptor to stimulate parathyroid hormone secretion. Nat Commun 10: 4693, 2019
Cunningham J, Locatelli F, Rodriguez M: Secondary hyperparathyroidism: Pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 6: 913–921, 2011
22Drueke T, Martin D, Rodriguez M: Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies. Nephrol Dial Transplant 22: 1828–1839, 2007
Dusso AS, Arcidiacono MV, Sato T, Alvarez-Hernandez D, Yang J, Gonzalez-Suarez I, Tominaga Y, Slatopolsky E. Molecular basis of parathyroid hyperplasia. J Ren Nutr. 2007;17:45–47
Fraser WD (July 2009). "Hyperparathyroidism". Lancet. 374 (9684): 145–58
Goodman WG, Quarles LD: Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics. Kidney Int 74: 276–288, 2008
Guo CJ, Leung PSC, Zhang W, et al.: The immunobiology and clinical features of type 1 autoimmune polyglandular syndrome (APS-1). Autoimmun Rev. 2018; 17(1): 78–85.
Hannan FM, Babinsky VN, Thakker RV: Disorders of the calcium-sensing receptor and partner proteins: Insights into the molecular basis of calcium homeostasis. J Mol Endocrinol. 2016; 57(3): R127–42.
Hans SK, Levine SN. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 18, 2021. Hypoparathyroidism
Hill NR, Fatoba ST, Oke JL et al. Global prevalence of chronic kidney disease—A systematic review and meta-analysis. PLoS ONE 2016;11(7):e0158765.
Hedgeman E., L. Lipworth, K. Lowe, R. Saran, T. Do, J. Fryzek. International burden of chronic kidney disease and secondary hyperparathyroidism: a systematic review of the literature and available data Int J Nephrol, 2015 (2015), p. 184321
Ketteler M , Block GA, Evenepoel P et al. Executive summary of the 2017 KDIGO chronic kidney disease–mineral and bone disorder (CKD–MBD) guideline update: what’s changed and why it matters. Kidney Int2017; 92: 26–
Kobrynski LJ, Sullivan KE: Velocardiofacial syndrome, DiGeorge syndrome: The chromosome 22q11.2 deletion syndromes. Lancet. 2007; 370(9596): 1443–52.
Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007;71(1):31–38.
Martin A, David V, Quarles LD: Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev 92: 131–155, 2012
Ming J, Cronin SJF and Penninger JM (2020) Targeting the RANKL/RANK/OPG Axis for Cancer Therapy. Front. Oncol. 10:1283. doi: 10.3389/fonc.2020.01283
Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006;69: 1945-1953.
Muppidi V, Meegada SR, Rehman A. Secondary Hyperparathyroidism. [Updated 2022 Aug 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557822/
Nechama M, Ben-Dov IZ, Briata P, Gherzi R, Naveh-Many T. The mRNA decay promoting factor K-homology splicing regulator protein post-transcriptionally determines parathyroid hormone mRNA levels. Faseb J. 2008;22:3458–3468.
Nosek, Thomas M. Essentials of Human Physiology. Archived from the original on 2016-03- 24.
Onal M, John HCSt., Danielson AL, Pike JW. Deletion of the Distal Tnfsf11 RL-D2 Enhancer That Contributes to PTH-Mediated RANKL Expression in Osteoblast Lineage Cells Results in a High Bone Mass Phenotype in Mice. Journal of Bone and Mineral Research, Vol. 31, No. 2, February 2016, pp 416–429
Pitt SC, Sippel RS, Chen H. Secondary and tertiary hyperparathyroidism, state of the art surgical management. Surg Clin North Am. 2009 Oct;89(5):1227-39
Powers J, Joy K, Ruscio A, et al.: Prevalence and Incidence of Hypoparathyroidism in the United States Using a Large Claims Database. J Bone Miner Res. 2013; 28(12): 2570–6
Rodriguez M, Felsenfeld AJ: PTH, FGF-23 and early CKD. Nephrol Dial Transplant 23: 3391– 3393, 2008
Tong X, Yu G, Fu X, Song R, Gu J, Liu Z. A Review of Signaling Transduction Mechanisms in Osteoclastogenesis Regulation by Autophagy, Inflammation, and Immunity. Int J Mol Sci. 2022 Aug 30;23(17):9846. doi: 10.3390/ijms23179846. PMID: 36077242; PMCID: PMC9456406.
